[{"id":"ddcdaa98-710f-4836-a6b4-89e5e80022ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05957367","created_at":"2023-07-24T15:08:40.775Z","updated_at":"2024-07-02T16:34:59.920Z","phase":"Phase 1/2","brief_title":"A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies","source_id_and_acronym":"NCT05957367","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" BRAF • KIT • PDGFRA","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KIT mutation • KIT exon 11 mutation • PDGFRA mutation","tags":["BRAF • KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KIT mutation • KIT exon 11 mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • Qinlock (ripretinib) • inlexisertib (DCC-3116)"],"overall_status":"Recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-31"},{"id":"adc60e89-0c9c-4cc8-bd12-3a3c5b7efc48","acronym":"","url":"https://clinicaltrials.gov/study/NCT01543113","created_at":"2021-01-18T06:31:19.399Z","updated_at":"2024-07-02T16:35:47.212Z","phase":"","brief_title":"cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project","source_id_and_acronym":"NCT01543113","lead_sponsor":"Rennes University Hospital","biomarkers":" KIT • RAS","pipe":" | ","alterations":" NRAS mutation • RAS mutation • KIT exon 11 mutation • KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • RAS mutation • KIT exon 11 mutation • KIT exon 13 mutation • KIT exon 17 mutation"],"overall_status":"Completed","enrollment":" Enrollment 288","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 03/01/2012","primary_completion_date":" 03/01/2012","study_txt":" Completion: 02/01/2014","study_completion_date":" 02/01/2014","last_update_posted":"2023-05-24"},{"id":"65aa546b-6373-4d3e-bd0b-ba34a643210e","acronym":"ZJGIST-01","url":"https://clinicaltrials.gov/study/NCT04933669","created_at":"2021-06-22T15:52:32.553Z","updated_at":"2024-07-02T16:36:23.163Z","phase":"Phase 2","brief_title":"Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT04933669 - ZJGIST-01","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 09/07/2021","start_date":" 09/07/2021","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2021-10-12"},{"id":"7eb24bb1-40e3-4e79-bff5-af65a3b0aeef","acronym":"","url":"https://clinicaltrials.gov/study/NCT00278876","created_at":"2021-01-18T00:57:00.626Z","updated_at":"2024-07-02T16:36:51.820Z","phase":"Phase 2","brief_title":"Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation","source_id_and_acronym":"NCT00278876","lead_sponsor":"Asan Medical Center","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation • KIT exon 11 mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 04/01/2005","start_date":" 04/01/2005","primary_txt":" Primary completion: 08/01/2007","primary_completion_date":" 08/01/2007","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2020-01-07"},{"id":"bd33213e-1e75-4d66-a7df-4eb6b35fb14c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01874665","created_at":"2021-01-17T17:54:42.275Z","updated_at":"2024-07-02T16:37:10.653Z","phase":"Phase 2","brief_title":"A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor","source_id_and_acronym":"NCT01874665","lead_sponsor":"Ariad Pharmaceuticals","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 06/05/2013","start_date":" 06/05/2013","primary_txt":" Primary completion: 02/28/2015","primary_completion_date":" 02/28/2015","study_txt":" Completion: 07/31/2016","study_completion_date":" 07/31/2016","last_update_posted":"2018-05-18"},{"id":"05655b81-f61f-4430-a051-3fbad631a8f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02776878","created_at":"2021-01-18T13:37:00.696Z","updated_at":"2024-07-02T16:37:32.017Z","phase":"","brief_title":"A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST","source_id_and_acronym":"NCT02776878","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT exon 11 mutation • PDGFRA mutation • KIT wild-type • PDGFRA exon 18 mutation • PDGFR wild-type","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT exon 11 mutation • PDGFRA mutation • KIT wild-type • PDGFRA exon 18 mutation • PDGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Unknown status","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2016-05-18"}]